Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles.
about
Antigenic subversion: a novel mechanism of host immune evasion by Ebola virusBoth Epistasis and Diversifying Selection Drive the Structural Evolution of the Ebola Virus Glycoprotein Mucin-Like DomainSpatial localization of the Ebola virus glycoprotein mucin-like domain determined by cryo-electron tomography.Camouflage and misdirection: the full-on assault of ebola virus diseaseShed GP of Ebola virus triggers immune activation and increased vascular permeabilityDetermination of specific antibody responses to the six species of ebola and Marburg viruses by multiplexed protein microarraysStructures of protective antibodies reveal sites of vulnerability on Ebola virus.Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.Fighting Ebola: A Window for Vaccine Re-evaluation?Development of a liquid chromatography high resolution mass spectrometry method for the quantitation of viral envelope glycoprotein in Ebola virus-like particle vaccine preparationsAn Ebola Virus-Like Particle-Based Reporter System Enables Evaluation of Antiviral Drugs In Vivo under Non-Biosafety Level 4 Conditions.Comprehensive functional analysis of N-linked glycans on Ebola virus GP1.Ebola virus entry into host cells: identifying therapeutic strategies.Viral O-GalNAc peptide epitopes: a novel potential target in viral envelope glycoproteins.Enhancement of Ebola Virus Infection via Ficolin-1 Interaction with the Mucin Domain of GP Glycoprotein.The roles of ebolavirus glycoproteins in viral pathogenesis.Vesicular stomatitis virus pseudotyped with Ebola virus glycoprotein serves as a protective, non-infectious vaccine against Ebola virus challenge in mice.Epitope-mapping of the glycoprotein from Crimean-Congo hemorrhagic fever virus using a microarray approachImmunogenicity of propagation-restricted vesicular stomatitis virus encoding Ebola virus glycoprotein in guinea pigsAntibody Repertoires to the Same Ebola Vaccine Antigen Are Differentially Affected by Vaccine Vectors
P2860
Q27339643-76D4D5B3-57F0-4F3E-9BFA-404502178D83Q28596689-9D226200-569F-49EE-9DA2-FBD1FD83B400Q30409973-C5A469D3-7436-423E-880B-AA93FC690967Q34449079-0561E2A0-2023-4795-A180-F57AF7C6AD86Q34550148-FC4EE4A9-789C-428D-B0B4-6E373CD2119AQ34593045-BB48FC10-BFE4-47CF-8EDE-D7026091299BQ34661120-811960D1-F286-45FD-ABF9-9C267952FF44Q36043290-04BB65AC-12CC-46B1-9515-18ADA79ADE02Q36247762-E9328217-7A2D-45BD-9C60-F434FD81FB56Q37232054-533FB3F9-AA3F-4309-B3B9-AA087E87EE7FQ37252982-8806DA1C-438E-406E-8513-7736B65700A2Q37631492-0EA0969F-8287-4B3D-9FBB-A1F86809B19CQ38618148-9FA2A290-605B-49A7-99A1-CD8B674E7EC1Q38622432-BEA760D3-51A1-43D2-B877-286FA45CCD21Q38785688-B2CB3FFA-8D39-4B14-A88B-3C9BDEB225BEQ39010678-37495089-A916-4221-B485-77EC81B25050Q40052567-9B18893D-62EA-4E8A-A699-FFB486CBDB60Q56395419-F6B8585E-F95D-407E-B622-5AA4B6236F58Q57197569-B8E9DEC8-212D-46EE-832B-3075C5FD5723Q58779740-C4AE131D-E723-4759-9FD2-9A503A495CE5
P2860
Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles.
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Impact of Ebola mucin-like dom ...... by Ebola virus-like particles.
@ast
Impact of Ebola mucin-like dom ...... by Ebola virus-like particles.
@en
type
label
Impact of Ebola mucin-like dom ...... by Ebola virus-like particles.
@ast
Impact of Ebola mucin-like dom ...... by Ebola virus-like particles.
@en
prefLabel
Impact of Ebola mucin-like dom ...... by Ebola virus-like particles.
@ast
Impact of Ebola mucin-like dom ...... by Ebola virus-like particles.
@en
P2093
P2860
P356
P1476
Impact of Ebola mucin-like dom ...... by Ebola virus-like particles
@en
P2093
Kartik Chandran
Lee Tantral
Nirupama Mulherkar
P2860
P304
P356
10.1093/INFDIS/JIR295
P407
P478
204 Suppl 3
P577
2011-11-01T00:00:00Z